Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling

NCT05179824 is registered in ClinicalTrials.gov with Tempus AI as lead sponsor.

NCT NCT05179824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05179824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling
Lead sponsor
Tempus AI
Phase
Observational
Overall status
Active, not recruiting
Start date
October 19, 2020
Completion date
October 19, 2030
Enrollment
1,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, brain cancer, breast cancer, cancer of bone and connective tissue, cancer of cervix, cancer of colon, cancer of endometrium, cancer of esophagus, cancer of gastrointestinal tract, cancer of head and neck, cancer of kidney, cancer of larynx, cancer of liver, cancer of rectum, cancer of skin, cancer of stomach, cancer of the bile duct, cancer of vulva, fallopian tube cancer, leukemia, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, spinal cord cancer